Training in Respiratory Medicine Genoa University   Turin University Ph.D in Oncology program   ERC   Training in Oncology RCPI appraised

CCT   Program Finalised   PhD eq   CCT

1988   1994   1993   2012

Respiratory medicine   Medical Oncology   Medical Oncology   Medical Oncology

 

• Adj Professor Translational Oncology. Sbarro Institute for Cancer Research and Molecular Medicine, Department of Biology, College of Science and Technology, Temple University, PA , US
• Professor Oncology and Head of the Dep of Oncology , University of L’Aquila , Italy 
• Past Chair in Cancer Research, Salford University, Salford, Greater Manchester, UK   

As per my list of peer reviewed publications, my most relevant ability is bridging the gap between the preclinical and clinical activities. This approach covers several human tumors even though we have been addressing our efforts mainly toward thoracic malignancies and particularly MM.

I have a long and successful experience as a leader of a big translational group of pre-clinical and clinical scientist working on this tumor and I have been contributing to European Guidelines for MM  from 2010 to date. As a Director of the Scientific Committee of Buzzi Foundation for study and Therapy of MM and Head of Dept  in Vercelli Teaching University Hosp, I  have been leading a multidisciplinary group  including Molecular Biology, Epidemiology and Molecular Epidemiology and Clinical Sciences. I have successfully conducted many studies requiring the coordination of a complex international team including Hospital and Academic Institutions.The outcome of these activities have allowed for new front line therapies for MPM as detailed in the Section C below   

More in general terms I have studied the immune response to MM as it follows: I have published the first paper suggesting that Mesothelioma cells have the potential to elicit a T-cell mediated immune response, however  the same tumor cells  induce immune-suppression via TGFb and AKT activation  although do express Cancer Testis Antigens (CTA).I  have also  provided with the rationale of using anti-CTLA4 for MPM and tested their efficacy for MPM in the first  trial ever conducted worldwide. 

Contributions to Science

All of my translational research activity is aimed at leading as a PI  and managing multidisciplinary groups to translate of  our pre-clinical findings on thoracic tumors  into clinical practice and  clinical trials. The current front line therapy for Mesothelioma including antiangiogenic is the direct outcome of our preclinical and translational studies. I pioneered research on Mesothelioma back in early 90s, and started, together with Marie Claude Jaurand, Bruce Robinson and a few others, the IMIG in Paris in 1993. I have dedicated the career to the care of patients with mesothelioma to develop new treatments based on solid preclinical research. 

Contribution to Mesothelioma and Lung Cancer:  

• Use of Antiangiogenic for MPM
• Role of actionable TKI and PI3K/AKT signaling in MPM  
• Immune Check Inhibitor (ICI) and PARPi as novel therapeutic tools against MPM and Lung Cancer
• European Guidelines for Mesothelioma, and Lung Cancer
• Viral Carcinogenesis and MPM 

Here below the link to my publications on Mesothelioma so far as per those listed on pubmed.gov: 

https://pubmed.ncbi.nlm.nih.gov/?term=Mutti+L.+Mesothelioma&sort=date